1Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 2Abramson Cancer Center and Abramson Family Cancer Research Institute, University of ...

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...

In a letter addressed to NIH director Jay Bhattacharya, MD, dubbed the Bethesda Declaration, NIH staff members criticized many of the agency’s actions under the Trump administration. Representing all ...

Findings from a phase I/II trial provide clinical proof-of-concept for a first-in-class mRNA-encoded T-cell engager targeting CLDN6 and CD3. Produced in vivo, the bispecific was well tolerated and had ...

Radiation Research Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland. *Corresponding Author: Jeffrey C. Buchsbaum, Radiation Research Program, Division of Cancer Treatment ...

SYNC-T, an investigational approach combining in situ vaccination, via partial tumor cryolysis, with intratumoral delivery of a cocktail of four immunotherapy agents, appears highly effective in ...

*Corresponding Author: Mara H. Sherman, Cancer Biology & Genetics, Memorial Sloan Kettering Cancer Center, 417 East 68th Street, 1261, New York, NY 10065. E-mail: [email protected] ...

Major Finding: Serotonin transporter depletes intratumoral serotonin which dampens CD8 + T-cell antitumor immunity. Concept: Serotonin transporter inhibition with SSRIs drives T-cell antitumor ...

According to a newly published article, immune cells with a loss of the Y chromosome (LOY) are less equipped to attack cancer cells than their Y chromosome-containing counterparts (Nature 2025 Jun 4 ...

The FDA today approved Bayer’s darolutamide (Nubeqa) for metastatic castration-sensitive prostate cancer (mCSPC) with or without chemotherapy. The decision was based on the results of the phase III ...

According to the international phase III NIVOPOSTOP trial, Bristol Myers Squibb’s PD-1 inhibitor nivolumab (Opdivo) added to adjuvant chemoradiotherapy can cut the risk of disease recurrence in ...

1Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. 2Department of Radiation Oncology, Harbin Medical University Cancer Hospital, Harbin, ...